Lovapres Plus

Amlodipine & Olmesartan Medoxomil BP

COMPOSITION

Lovapres Plus 5/20 Tablet: Each film coated tablet contains Amlodipine Besilate BP equivalent to Amlodipine 5 mg and Olmesartan Medoxomil BP 20 mg. Lovapres Plus 5/40 Tablet: Each film coated tablet contains Amlodipine Besilate BP equivalent to Amlodipine 5 mg and Olmesartan Medoxomil BP 40 mg.

PHARMACOLOGY

It is a combination of two antihypertensive drugs Amlodipine Besilate and Olmesartan Medoxomil. Amlodipine Besilate is a calcium channel blocker and Olmesartan Medoxomil is an angiotensin II receptor blocker.

Amlodipine inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction in blood pressure.

Olmesartan Medoxomil, a prodrug is hydrolyzed to Olmesartan during absorption from the gastrointestinal tract. It blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle.

INDICATION

This combination is indicated for the treatment of hypertension, alone or with other antihypertensive drugs to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions.

It may also be used as initial therapy in patients likely to need multiple antihypertensive drugs to achieve their blood pressure goals.

DOSAGE AND ADMINISTRATION

The usual starting dose of this is 5/20 mg once daily. The dosage can be increased after 1 to 2 weeks of therapy to a maximum dose of 10/40 mg tablet once daily as needed to control blood pressure.

CONTRAINDICATION

Do not co-administer Aliskiren with it in patients with diabetes.

WARNING & PRECAUTION

• Anticipate hypotension in volume or salt-depleted patients with treatment initiation and start treatment under close supervision.

• Increased angina or myocardial infarction may occur upon dosage initiation or increase.

· Changes in renal function may occur.

• Sprue-like enteropathy has been reported. Consider discontinuation of it in cases where no other etiology is found.

SIDE EFFECTS

The most common side effect (incidence ≥3%) is edema.

USE IN PREGNANCY & LACTATION

Pregnancy: When pregnancy is detected, discontinue it as soon as possible. Consider alternative antihypertensive therapy during pregnancy. **Lactation:** Not recommended.

USE IN CHILDREN & ADOLESCENT

Safety and effectiveness of it in paediatric patients have not been established.

DRUG INTERACTION

Simvastatin: Increased exposure of Simvastatin. Do not exceed 20 mg daily dose of Simvastatin.

Cyclosporine and Tacrolimus: Increased exposure of Cyclosporine and Tacrolimus.

CYP3A inhibitors: Increased exposure of Amlodipine.

Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension and hyperkalemia.

Colesevelam Hydrochloride: Consider administering Olmesartan at least 4 hours before Colesevelam Hydrochloride dose.

Lithium: Increases in serum Lithium concentrations and Lithium toxicity.

NSAIDs: May lead to increased risk of renal impairment and loss of antihypertensive effect.

OVERDOSAGE

There is no information on overdosage with this combination in humans.

STORAGE

Store below 30° C temperature in a cool & dry place. Protect from light & moisture. Keep out of the reach of children.

HOW SUPPLIED

Lovapres Plus 5/20 Tablet: Each box contains 30 tablets in Alu-Alu blister pack. Lovapres Plus 5/40 Tablet: Each box contains 30 tablets in Alu-Alu blister pack.

